National public-private consortium aims to bring together researchers, oncologists, knowledge institutes and the business community to collaboratively develop better and affordable cancer medicines more quicklyDURHAM, N.C. (BUSINESS WIRE) Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) te.
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will participate